Published in BMC Cancer on November 18, 2010
The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int (2013) 0.90
Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol (2016) 0.86
Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. Oncotarget (2014) 0.86
New and emerging treatment options for biliary tract cancer. Onco Targets Ther (2013) 0.85
Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol (2013) 0.84
Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res (2014) 0.84
Targeted Therapy in Biliary Tract Cancers. Curr Treat Options Oncol (2015) 0.83
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. Tumour Biol (2015) 0.81
Molecular biology of gallbladder cancer: potential clinical implications. N Am J Med Sci (2012) 0.80
A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Arch (2016) 0.79
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer (2014) 0.79
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. Oncotarget (2016) 0.78
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Invest New Drugs (2011) 0.78
HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World J Gastroenterol (2016) 0.78
Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. World J Gastroenterol (2016) 0.77
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs (2014) 0.75
Evaluation of P53, E-cadherin, Cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma. Arq Bras Cir Dig (2014) 0.75
Identification of the Calmodulin-Binding Domains of Fas Death Receptor. PLoS One (2016) 0.75
HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev (2016) 0.75
Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing. Oncotarget (2016) 0.75
Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. Oncotarget (2017) 0.75
A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis (2016) 0.75
KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers. Jpn Clin Med (2016) 0.75
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. BMC Cancer (2016) 0.75
Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol (2017) 0.75
Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Growth factors and cancer. Science (1991) 4.54
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
EGF receptor. Int J Biochem Cell Biol (1999) 3.91
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut (2003) 3.91
Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol (2006) 3.31
The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer (2005) 2.83
The role of the EGFR signaling in tumor microenvironment. J Cell Physiol (2008) 2.34
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res (2003) 2.33
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer (2007) 2.09
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol (2008) 1.66
Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48
The role of chemotherapy in cholangiocarcinoma. Ann Oncol (2005) 1.46
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res (2006) 1.44
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer (2005) 1.41
Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion. Gastroenterology (1999) 1.26
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol (2007) 1.25
The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res (2009) 1.21
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet (2007) 1.20
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer (2008) 1.15
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol (2007) 1.03
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol (2006) 1.02
Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest (1999) 1.01
Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer (2010) 0.96
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs (2006) 0.95
Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology (2002) 0.94
Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol (2000) 0.93
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol (2008) 0.91
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. Cancer Sci (2009) 0.90
Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol (2000) 0.89
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer (2009) 0.85
Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinog (1992) 0.82
Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. Int J Biol Markers (2007) 0.79
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
International network of cancer genome projects. Nature (2010) 20.35
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology (2007) 3.78
Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst (2011) 3.75
Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev (2006) 3.72
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol (2013) 3.67
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE. J Natl Cancer Inst (2002) 3.00
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev (2007) 2.61
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res (2013) 2.61
Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst (2005) 2.51
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol (2011) 2.21
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res (2007) 1.98
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther (2012) 1.91
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem (2006) 1.85
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol (2010) 1.80
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med (2014) 1.79
High commitment of embryonic keratinocytes to terminal differentiation through a Notch1-caspase 3 regulatory mechanism. Dev Cell (2004) 1.78
Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood (2011) 1.76
Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res (2004) 1.68
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist (2006) 1.65
c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell (2006) 1.64
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat (2004) 1.62
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology (2011) 1.61
HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park) (2002) 1.61
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res (2010) 1.51
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res (2012) 1.51
Sema4C-Plexin B2 signalling modulates ureteric branching in developing kidney. Differentiation (2010) 1.48
Translocation-related sarcomas. Semin Oncol (2009) 1.45
Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol (2006) 1.45
Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood (2010) 1.44
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res (2006) 1.44
Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients. Ann Surg Oncol (2012) 1.44
PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res (2005) 1.43
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol (2010) 1.42
Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Hum Mutat (2013) 1.42
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest (2010) 1.41
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest (2007) 1.39
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res (2005) 1.37
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood (2007) 1.35
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One (2010) 1.35
Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res (2011) 1.32
Targeted therapies: how personal should we go? Nat Rev Clin Oncol (2011) 1.31
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer (2012) 1.30
PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat (2008) 1.29
Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells (2012) 1.26
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer (2013) 1.26
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest (2004) 1.25
Structure and function of the intracellular region of the plexin-b1 transmembrane receptor. J Biol Chem (2009) 1.24
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol (2010) 1.20
SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc Natl Acad Sci U S A (2004) 1.20
The FoxO3a gene is a key negative target of canonical Notch signalling in the keratinocyte UVB response. EMBO J (2008) 1.20
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer (2009) 1.20
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant (2009) 1.19